FrancophonIA/ELRC3.0 huggingface dataset:
English: The onset time is ≤ 3 days post-zoledronic acid infusion (used as indicated in sections 4.1 and 4.2), and the reaction is also referred to using the terms “flu-like” or “post-dose” symptoms.
Estonian: Sümptomid võivad tekkida maksimaalselt kolme päeva jooksul pärast zoledroonhappe infundeerimist ja reaktsiooni nimetatakse ka gripilaadseteks või annustamisjärgseteks sümptomiteks.
English: Rare (may affect up to 1 in 1,000 people): - Slow heart beat.
Estonian: Harv (võivad esineda kuni 1 inimesel 1000-st):
English: Patients should have their serum creatinine levels assessed prior to each dose of Zoledronic acid Actavis.
Estonian: Enne iga Zoledronic acid Actavis'e annuse manustamist tuleb määrata patsiendil seerumi kreatiniinisisaldus.
English: Instructions for preparing reduced doses of Zoledronic acid Actavis Withdraw an appropriate volume of the concentrate needed, as follows: - 4.4 ml for 3.5 mg dose
Estonian: Juhend vähendatud annusega Zoledronic acid Actavis'e lahjendatud lahuse valmistamiseks Võtke vajalik kogus kontsentraati vastavalt:
English: Name and address of the manufacturer responsible for batch release
Estonian: Ravimipartii kasutamiseks vabastamise eest vastutava(te) tootja(te) nimi ja aadress Actavis Italy S.p.A
English: MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Estonian: RAVIMPARTII KASUTAMISEKS VABASTAMISE EEST VASTUTAV(AD) TOOTJA(D)
English: - Chest pain.
Estonian: − Valu rinnus.
English: The hydration status of patients must be assessed prior to and following administration of Zoledronic acid Actavis to ensure that they are adequately hydrated.
Estonian: Enne ja pärast ravimi manustamist tuleb kontrollida, kas patsient on piisavalt hüdreeritud.
English: Very rare (may affect up to 1 in 10,000 people): - As a consequence of low calcium values: seizures, numbness and tetany (secondary to hypocalcaemia).
Estonian: − Madal kaltsiumisisaldus veres võib põhjustada: krampe, tuimust ja tetaaniat (sekundaarsena hüpokaltseemiast).
English: Tell your doctor immediately if you experience symptoms such as new onset or worsening of aches, pain or stiffness while being treated with Zoledronic acid Actavis or after stopping treatment.
Estonian: Kui teil esinevad Zoledronic acid Actavis-ravi ajal või pärast ravi lõppu sümptomitena valu, valuhoogude või jäikuse teke või ägenemine, rääkige sellest kohe oma arstile.
English: Common (may affect up to 1 in 10 people): - Headache and a flu-like syndrome consisting of fever, fatigue, weakness, drowsiness, chills and bone, joint and/or muscle ache.
Estonian: − Peavalu ja gripitaoline sündroom (palavik, väsimus, nõrkus, uimasus, külmavärinad ning luu-,
English: Hypophosphataemia
Estonian: hüpofosfateemia sage:
English: Gastrointestinal disorders Very common:
Estonian: Üldised häired ja manustamiskoha reaktsioonid Väga sage:
English: Ref.: EMEA/503246/2009 EMEA/H/C/1054
Estonian: Viide: EMEA/503253/2009 EMEA/H/C/1054
English: In acute coronary syndrome, Clopidogrel 1A Pharma is used together with aspirin and treatment generally starts with a loading dose of four 75 mg tablets.
Estonian: Akuutse koronaarsündroomi korral kasutatakse Clopidogrel 1A Pharmat koos aspiriiniga; ravi algab üldiselt küllastusannusega, kus võetakse neli 75 mg tabletti.
English: The standard dose of Clopidogrel 1A Pharma is one 75 mg tablet once a day, taken with or without food.
Estonian: Clopidogrel 1A Pharma tavaannus on üks 75 mg tablett üks kord ööpäevas koos toiduga või ilma.
English: Clopidogrel 1A Pharma can be used in patients who are having myocardial infarction with ‘ST segment elevation' (an abnormal reading on the electrocardiogram or ECG) when the doctor thinks that they would benefit from the treatment.
Estonian: Clopidogrel 1A Pharmat võib manustada ka patsientidele, kellel on ST-segmendi elevatsiooniga (elektrokardiogrammi ehk EKG teatud ebanormaalne näit) südameinfarkt, kui arst arvab, et ravimist on patsiendile kasu.
English: Clopidogrel 1A Pharma can be given to the following groups of patients:
Estonian: Clopidogrel 1A Pharmat võib kasutada järgmiste patsiendirühmade korral:
English: Because Clopidogrel 1A Pharma is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Estonian: Et Clopidogrel 1A Pharma on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: This means that Clopidogrel 1A Pharma is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix.
Estonian: See tähendab, et Clopidogrel 1A Pharma on sarnane võrdlusravimiga Plavix, millel juba on Euroopa Liidus müügiluba.
English: Clopidogrel 1A Pharma can be started between seven days and six months after
Estonian: Clopidogrel 1A Pharma manustamist võib alustada seitsme päeva kuni kuue kuu jooksul pärast insulti;
English: Clopidogrel 1A Pharma can be started between a few days and 35 days after the attack;
Estonian: Clopidogrel 1A Pharma manustamist võib alustada mõne kuni 35 päeva jooksul pärast infarkti;
English: The European Commission granted a marketing authorisation valid throughout the EU for Clopidogrel 1A Pharma to Acino Pharma GmbH on 28 July 2009.
Estonian: Euroopa Komisjon andis Clopidogrel 1A Pharma müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Acino Pharma GmbH.
English: The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Clopidogrel 1A Pharma has been shown to have comparable quality and to be bioequivalent to Plavix.
Estonian: Inimravimite komitee otsustas, et vastavalt Euroopa Liidu nõuetele on tõendatud Clopidogrel 1A Pharma võrdväärne kvaliteet ja bioekvivalentsus ravimiga Plavix.
English: The Committee recommended that Clopidogrel 1A Pharma be given marketing authorisation.
Estonian: Komitee soovitas anda Clopidogrel 1A Pharmale müügiloa.
English: Clopidogrel 1A Pharma clopidogrel EPAR summary for the public
Estonian: Clopidogrel 1A Pharma klopidogreel Kokkuvõte üldsusele
English: Clopidogrel 1A Pharma is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries).
Estonian: Clopidogrel 1A Pharmat kasutatakse aterotrombootiliste nähtude (trombide ehk soonesiseste verehüüvete moodustumisest ja arterite lubjastumisest põhjustatud probleemide) ennetamiseks täiskasvanutel.
English: Clopidogrel 1A Pharma is a medicine that contains the active substance clopidogrel.
Estonian: Clopidogrel 1A Pharma on ravim, mis sisaldab toimeainena klopidogreeli.
English: Because Clopidogrel 1A Pharma is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Estonian: Et Clopidogrel 1A Pharma on geneeriline ravim, piirdusid uuringud katsetega, milles näidati Clopidogrel 1A Pharma bioekvivalentsust võrdlusravimiga Plavix.
English: The full EPAR for Clopidogrel 1A Pharma can be found here.
Estonian: Euroopa avaliku hindamisaruande täisteksti Clopidogrel 1A Pharma kohta leiate siit.
English: Clopidogrel 1A Pharma is a ‘generic medicine'.
Estonian: Clopidogrel 1A Pharma on geneeriline ravim.
English: Other information about Clopidogrel 1A Pharma:
Estonian: Muu teave Clopidogrel 1A Pharma kohta
English: Therefore, the CHMP's view was that, as for Plavix, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Plavixi puhul, ületab Clopidogrel 1A Pharma kasulikkus sellega kaasnevad riskid.
English: What is Clopidogrel 1A Pharma?
Estonian: Mis on Clopidogrel 1A Pharma?
English: Why has Clopidogrel 1A Pharma been approved?
Estonian: Miks Clopidogrel 1A Pharma heaks kiideti?
English: How has Clopidogrel 1A Pharma been studied?
Estonian: Kuidas Clopidogrel 1A Pharmat uuriti?
English: The active substance in Clopidogrel 1A Pharma, clopidogrel, is an inhibitor of platelet aggregation.
Estonian: Clopidogrel 1A Pharma toimeaine klopidogreel on trombotsüütide agregatsiooni (vereliistakute kokkukleepumise) inhibiitor, See aitab ennetada organismis trombide tekkimist.
English: How is Clopidogrel 1A Pharma used?
Estonian: Kuidas Clopidogrel 1A Pharmat kasutatakse?
English: How does Clopidogrel 1A Pharma work?
Estonian: Kuidas Clopidogrel 1A Pharma toimib?
English: What are the benefit and risk of Clopidogrel 1A Pharma?
Estonian: Milles seisneb Clopidogrel 1A Pharma kasulikkus ja mis riskid ravimiga kaasnevad?
English: • patients who have a condition known as ‘acute coronary syndrome', when it should be given with aspirin (another medicine that prevents blood clots), including patients who have had a stent inserted (a short tube placed in an artery to prevent it closing up).
Estonian: Sel juhul tuleb Clopidogrel 1A Pharmat manustada koos aspiriiniga (samuti antikoagulant), sealhulgas patsientidele, kellele on paigaldatud stent (ahenenud arterit avardav väike toru).
English: Results are heterogeneous and inconsistent.
Estonian: Tulemused on heterogeensed ja ebajärjepidevad.
English: (PAOD Stage II)
Estonian: (PAOD, II staadium)
English: Its effect results mainly from its α1-blocking properties.
Estonian: Toime peamine alus on α1-blokeerivad omadused.
English: (excluding Alzheimer's disease and other dementia)
Estonian: Alzheimeri tõbi ja muu dementsus)
English: Of these, 18 concerned placebocontrolled trials, 2 concerned actively-controlled trials and 7 concerned open label studies.
Estonian: Neist 18 käsitlesid platseebokontrolliga, 2 aktiivkontrolliga ja 7 avatud uuringuid.
English: Overall summary of the scientific evaluation of dihydroergocristine containing medicinal products (see Annex I)
Estonian: Dihüdroergokristiini sisaldavate ravimite (vt I lisa) teadusliku hindamise üldkokkuvõte
English: On 18 January 2012, France triggered a referral under Article 31 of Directive 2001/83/EC for the following ergot derivatives containing medicinal products: dihydroergocryptine/caffeine, dihydroergocristine, dihydroergotamine, dihydroergotoxine and nicergoline.
Estonian: 18. jaanuaril 2012 tegi Prantsusmaa direktiivi 2001/83/EÜ artikli 31 kohase esildise järgmiste tungalteraalkaloide sisaldavate ravimite kohta: dihüdroergokrüptiin/kofeiin, dihüdroergokristiin, dihüdroergotamiin, dihüdroergotoksiin ja nikergoliin.
English: In six of the evaluable studies with population under 100 patients there were similar findings.
Estonian: Sarnased tulemused olid ka 6 hinnatavas uuringus, milles osales alla 100 patsiendi.
English: There were 3 placebo controlled studies with a study population of 200-240 patients.
Estonian: 3 uuringus kasutati platseebokontrolli ja osales 200-240 patsienti.
English: Grounds for the variation/suspension to the terms of the marketing authorisations
Estonian: Müügilubade tingimuste muutmise/peatamise alused
English: The CHMP was therefore requested to give its opinion on whether the marketing authorisations for ergot derivatives containing medicinal products should be maintained, varied, suspended or withdrawn in relation to the below mentioned indications:
Estonian: Inimravimite komiteel paluti seepärast anda arvamus, kas tungalteraalkaloide sisaldavate ravimite müügiload tuleb alljärgnevate näidustuste korral säilitada, muuta, peatada või tagasi võtta:
English: • Orthostatic hypotension
Estonian: • Ortostaatiline hüpotensioon
English: However, in this study with adequate methodological quality standard, non-significant difference between dihydroergocristine + raubasine and placebo groups was observed.
Estonian: Paraku täheldati selles adekvaatses metodoloogilise kvaliteedistandardiga uuringus, et dihüdroergokristiini + raubasiini rühma ja platseeborühma tulemuste erinevus ei olnud oluline.
English: Although some of the proposed measures could help identify patients with pre-existing fibrosis, relevant concomitant medication and increased risk, the Committee pointed out that they are insufficient to avoid that some patients develop fibrosis and ergotism during treatment.
Estonian: Kuigi pakutud meetmetest mõni võiks aidata tuvastada olemasoleva fibroosiga patsiente, asjakohaseid kaasuvaid ravimeid ja suurenenud riski, juhtis komitee tähelepanu sellele, et meetmetest ei piisa, et välistada mõnel patsiendil ravi ajal fibroosi ja ergotismi teket.
English: The CHMP has considered the totality of the available data on the safety and efficacy of dihydroergocristine.
Estonian: Inimravimite komitee vaatas läbi kõik olemasolevad andmed dihüdroergokristiini ohutuse ja efektiivsuse kohta.
English: There are 2 further studies by Hugonot et al with population of 114-127 patients, both showing superiority over placebo.
Estonian: 2 muud uuringut (Hugonot et al.), kus osales 114-127 patsienti, tõendavad mõlemad paremust platseeboga võrreldes.
English: Of the 6 randomised, double blind, placebo-controlled studies, 5 studies were not considered relevant by the CHMP because the definition of the diagnosis was not standardised, no primary efficacy criterion was selected among the multi-dimensional assessment, the number of patients per group was small (from 47 to 65), and the treatment duration was short (2 and 3 months).
Estonian: Inimravimite komitee ei pidanud 5 randomiseeritud topeltpimedat platseebokontrolliga uuringut 6st asjakohaseks, sest diagnoos ei olnud standardiseeritud, mitmemõõtmelisele hindamisele vaatamata ei olnud valitud esmast efektiivsuskriteeriumi, patsientide arv rühmas oli väike (47-65) ja ravi kestus lühike (2 ja 3 kuud).
English: Among these 3 studies, the publications by Lazzaroni et al and Aranda et al indicated superiority over placebo, while the study by Vellas et al demonstrated similar efficacy to placebo.
Estonian: Nendest 3 uuringust tõendasid publikatsioonid Lazzaroni et al. ja Aranda et al. paremust platseeboga võrreldes, kuid uuring Vellas et al. platseeboga sarnast efektiivsust.
English: The CHMP was of the opinion that no efficacy conclusion could be drawn based on these studies.
Estonian: Komitee järeldas, et nende uuringute alusel ei saa efektiivsuse kohta midagi järeldada.
English: • The Committee considered the procedure under Article 31 of Directive 2001/83/EC for ergot derivatives containing medicinal products in the concerned indications.
Estonian: • inimravimite komitee arutas direktiivi 2001/83/EÜ artikli 31 kohast esildist tungalteraalkaloide sisaldavate ravimite kasutamise kohta asjaomastel näidustustel;
English: In Europe, dihydroergocristine is also available in combination with etofyllinum.
Estonian: Euroopas turustatakse dihüdroergokristiini ka kombinatsioonis etofülliiniga.
English: The most recent study (Vellas 1998 - Not published) that became available after the granting of the initial marketing autohrisation, uses a standardised definition of diagnosis (patients had to present a moderate memory deficit, with a Mini-Mental Sate Examination MMSE > 25 and a score total > 38 and < 70 on the Mac Nair and Kahn auto-questionnaire assessing the difficulties in daily activities) and defines the primary efficacy criterion a priori (the Mac Nair and Kahn auto-questionnaire and the Gröber and Buschke test).
Estonian: Kõige uuemas uuringus (Vellas 1998, avaldamata), mille andmed saadi pärast esialgse müügiloa andmist, kasutatakse diagnoosi standardmääratlust (patsientidel pidi keskmine mäludefitsiit vaimse seisundi Mini-Mental-testi (MMSE) skaalal olema > 25 ja igapäevategevuse raskusi hindava MacNairi ja Kahni enesehindamise küsimustiku koguskoor > 38 ja < 70) ning määratleb esmase efektiivsuskriteeriumi a priori (Mac Nairi ja Kahni enesehindamise küsimustik ning Gröberi ja Buschke test).
English: It produces a decrease in blood pressure and an increase in peripheral blood flow.
Estonian: Ravim langetab vererõhku ja soodustab perifeerset verevarustust.
English: Moreover, it was pointed out that topical instillations of dihydroergocristine are out of the scope of this procedure.
Estonian: Samuti märgiti, et dihüdroergokristiini toopiline instilleerimine ei ole käesoleva menetluse käsitlusalas.
English: This is indicative of a causal relationship between fibrosis and dihydroergocristine.
Estonian: See näitab fibroosi ja dihüdroergokristiini vahelist põhjuslikku seost.
English: • The Committee considered that the benefit-risk balance of dihydroergocristine containing products:
Estonian: • komitee järeldas, et dihüdroergokristiini sisaldavate ravimite kasulikkuse ja riski tasakaal:
English: Dihydroergocristine is a partial agonist of α-adrenoreceptors that decreases the activity of sympathetic centres and is responsible for a peripheral adrenolytic effect with an increased venous wall tone.
Estonian: Dihüdroergokristiin on α-adrenoretseptorite osaline agonist, mis vähendab sümpaatiliste keskuste aktiivsust ja tekitab veeniseina suurenenud toonuse kaudu perifeerse adrenolüütilise efekti.
English: Therefore, other mechanisms inducing fibrosis cannot be excluded, which suggests a causal link between fibrosis and agonism of 5-HT2A and 5-HT1B receptors and also plausible effect on serotonin transporter.
Estonian: Seega ei saa välistada teisi fibroosi põhjustavaid mehhanisme, mispärast võib oletada fibroosi ning 5-HT2A ja 5-HT1B retseptorite agonismi põhjuslikku seost ning ühtlasi tõenäolist mõju serotoniini transporterile.
English: While it is agreed that the medical terminology used nowdays and in the past differs and that the data needs to be assessed bearing this aspect in mind, the clinical symptom of dementia is a result of various pathophysiological processes which makes pooling and comparison of the data difficult, especially when the individual studies used slightly different inclusion criteria.
Estonian: Kuigi tänapäevane meditsiiniterminoloogia erineb varasemast, mida tuleb meeles pidada andmeid hinnates, on dementsus kliinilise sümptomina mitmesuguste patofüsioloogiliste protsesside tulemus, mis raskendab andmete kogumist ja võrdlemist, eriti kui eri uuringutes kasutati mõnevõrra erinevaid uuringusse kaasamise kriteeriume.
English: In order to lift the suspension, MAHs must identify a specific patient population for which the benefits of the product outweigh the identified risk.
Estonian: Müügiloa peatamise lõpetamiseks peavad müügiloa hoidjad tuvastama konkreetse patsiendipopulatsiooni, kellel ületab ravimi kasulikkus sellega kaasnevad riskid.
English: Moreover the severity of such adverse effects, their possible fatal outcome and the raised risk for patient to develop a fibrotic disorder with long term use according to the authorised indications should be underlined.
Estonian: Samuti tuleb eraldi rõhutada nende kõrvaltoimete raskust, võimalikku fataalset lõpet ning suurenenud riski, et patsiendil võib heakskiidetud näidustuste ravis pikaajalisel kasutamisel tekkida fibrootiline seisund.
English: Therefore, even if it is highly pharmacologically plausible that ergot derivatives acting as 5HT2B receptor agonists may induce "serotonergic" valve disease similar to that induced by carcinoid tumours or fibrotic lesions of other tissues, it must be remembered that some ergot derivatives are not 5-HT2B receptor agonists.
Estonian: Isegi kui farmakoloogilisest aspektist on väga tõenäoline, et 5-HT2B retseptorite agonistidena toimivad tungalteraalkaloidid võivad põhjustada „serotonergilist” südameklappide haigust, mis sarnaneb kartsinoidkasvajate või muude kudede fibrootiliste lesioonide põhjustatud haigusega, tuleb ikkagi meeles pidada, et mõni tungalteraalkaloid ei ole 5-HT2B retseptori agonist.
English: From the approved indications of the dihydroergocristine containing medicinal products the ones that are in the scope of this referral procedure and are approved in at least one Member State are the following (specific wording of the indication may vary from product to product):
Estonian: Dihüdroergokristiini sisaldavate ravimite heakskiidetud näidustustest on käesoleva esildismenetluse käsitlusalas ja vähemalt ühes liikmesriigis heaks kiidetud järgmised (täpne sõnastus võib eri ravimitel olla erinev):
English: All the data submitted were reviewed and considered, and though it can be interpreted as suggestive of mild efficacy of dihydroergocristine in the”treatment of chronic cognitive impairment in the elderly”, efficacy cannot be considered as sufficiently demonstrated namely due to the inconsistency of the data generated in the larger trials.
Estonian: Kõik esitatud andmed vaadati läbi ja võeti arvesse, ning ehkki neid saab tõlgendada, nagu oleks dihüdroergokristiin näidustusel „kroonilise kognitiivse kahjustuse ravi eakatel” mõnevõrra efektiivne, ei saa efektiivsust pidada piisavalt tõendatuks, sest suurte uuringute tulemused on ebajärjekindlad.
English: The group highlighted that the claimed indication is not used anymore in the clinical practice and that from a clinical viewpoint there is no evidence at present that there is a therapeutic need for this active substance in the treatment of cognitive and neurosensorial impairment in the elderly.
Estonian: Nõuanderühm juhtis tähelepanu sellele, et kavandatavat näidustust kliinilises praktikas enam ei kasutata ja kliinilisest aspektist puuduvad praegu andmed, et eakate kognitiivse ja neurosensoore kahjustuse ravis oleks selle toimeaine järele terapeutilist vajadust.
English: The MAHs also submitted their own overviews and critical summaries of all spontaneous reports of fibrotic reactions (cardiac with or without pulmonary arterial hypertension, pulmonary, pleural, peritoneal, retroperitoneal, etc) and ergotism with their ergot derivatives-containing medicinal products.
Estonian: Müügilubade hoidjad esitasid ka nende enda koostatud ülevaated ja kriitilised kokkuvõtted kõigi nende turustatavate tungalteraalkaloide sisaldavate ravimitega seotud spontaansete teadete kohta, mis käsitlesid fibrootilisi reaktsioone (südamereaktsioonid koos pulmonaalse hüpertensiooniga või ilma, pulmonaalsed, pleuraalsed, peritoneaalsed, retroperitoneaalsed jne reaktsioonid) ja ergotismijuhtumeid .
English: A scientific advisory group (SAG) was convened in December 2012 at the request of the CHMP during which the experts discussed, based on their clinical experience, whether this substance plays a role in the symptomatic treatment of chronic pathological cognitive and neurosensorial impairment in elderly (excluding Alzheimer's disease and other dementia).
Estonian: Detsembris 2012 kutsuti inimravimite komitee nõudel kokku teadusnõuanderühm, mille eksperdid arutasid oma kliinilistele kogemustele toetudes küsimust, kas see aine on oluline eakate kroonilispatoloogilise kognitiivse ja neurosensoorse kahjustuse (v.a Alzheimeri tõve ja muu dementsuse) sümptomaatilises ravis.
English: The Committee concluded that the benefit-risk balance of dihydroergocristine containing products is not favourable pursuant to Article 116 of Directive 2001/83/EC for symptomatic treatment of chronic pathological cognitive and neurosensorial impairment in elderly (excluding Alzheimer's disease and other dementia), for ancillary treatment of visual acuity decrease and visual field disturbances presumably of vascular origin and for acute retinopathies of vascular origin.
Estonian: Inimravimite komitee järeldas, et dihüdroergokristiini sisaldavate ravimite kasulikkuse ja riski tasakaal ei ole direktiivi 2001/83/EÜ artikli 116 alusel eakate kroonilis-patoloogilise kognitiivse ja neurosensoorse kahjustuse (v.a Alzheimeri tõve ja muu dementsuse) sümptomaatilise ravi, eeldatavalt vaskulaarse põhjusega nägemisteravuse vähenemise ja nägemisvälja häirete täiendava ravi ning vaskulaarse põhjusega ägedate retinopaatiate korral soodne.
English: The data from the reported cases of fibrosis (n=12) are indicative of the capacity of dihydroergocristine to induce fibrotic reactions, mostly localised in the pulmonary area considering also the improvement of some patients following discontinuation of the product.
Estonian: Fibroosijuhtude teadete (n=12) andmed viitavad dihüdroergokristiini omadusele indutseerida fibrootilisi reaktsioone, enamasti kopsupiirkonnas, samuti sellele, et mõne patsiendi seisund ravimi kasutamise lõpetamisel paranes.
English: • Ancillary treatment of Raynaud's syndrome
Estonian: • Raynaud' sündroomi täiendav ravi